- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
No evidence to endorse efficacy: Ayush Ministry asks ASU drug makers to stop use of Aswagandha
New Delhi: The Ministry of AYUSH has recently directed Ayurveda, Siddha and Unani (ASU) drug manufacturers to refrain from use of Aswagandha (Withania somnifera) leaves, holding that no substantial evidence and literature is available to endorse the efficacy of crude drug or extract of Aswagandha.
In this regard, the Ministry has issued an advisory to All ASU Drugs Manufacturers Associations seeking the manufacturers of the crude drug/extracts, sellers, ASU drug manufacturing companies, ASU drug exporters not to use Withania somnjfera leaves either in crude or extract or any other form for therapeutic purposes under the ambit of ASU drugs as per textual indications or as a food supplements in the name of ASU drugs.
This comes after the Ministry noted that Ashwagandha leaves are being used by some manufacturers in their formulations.
As per the Ministry, Withania somnfera (Aswagandha) root is widely used drug in Ayurveda, Siddha and Unani (ASU) systems of medicine since ancient period. Ayurveda, Unani and Siddha systems refer the drug as Aswagandha, Asgandh and Amukkura respectively. Further, Ayurvedic Pharmacopoeia of India defines that the Asvagandha consists of dried mature roots of Withania somnfera Dunal (API, Part I, Vol.1). All these systems use roots of the Withania somnfera as useful part in different single and compound classical formulations.
As such, the use of leaves of Withania somnifera has not been reported in classical texts of ASU systems of medicine. However, some of the OTC formulations of Withania somnifera leaves are available in markets but neither their safety and efficacy is vividly studied nor reported in ASU classical texts, it said.
"No substantial evidence and literature is available to endorse the efficacy of crude drug/ extract of Withania somnifera leaves. Considering this, it would not be appropriate to consider the Withania somnifera leaves as ASU medicine at this stage", the Ministry observed.
It noted that extensive studies are required to establish the safety and efficacy of leaves of Withania somnifera for different indications. Till then, the usage of leaves may not be considered for therapeutic purpose in ASU systems.
To view the official advisory, click on the link below:
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751